Compare · ICVX vs NVO
ICVX vs NVO
Side-by-side comparison of Icosavax Inc. (ICVX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICVX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 405.2x ICVX ($543.9M).
- NVO has hit the wire 5 times in the past 4 weeks while ICVX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 10 for ICVX).
- Company
- Icosavax Inc.
- Novo Nordisk A/S
- Price
- $15.34-0.39%
- $41.18+6.93%
- Market cap
- $543.9M
- $220.35B
- 1M return
- -
- +13.32%
- 1Y return
- -
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ICVX
- Frazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation Team
- CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)
- SEC Form 15-12G filed by Icosavax Inc.
- SEC Form SC 13D/A filed by Icosavax Inc. (Amendment)
- SEC Form SC 13D/A filed by Icosavax Inc. (Amendment)
- SEC Form SC TO-T/A filed by Icosavax Inc. (Amendment)
- SEC Form EFFECT filed by Icosavax Inc.
- SEC Form 4 filed by Ra Capital Management, L.P.
- Simpson Adam K. closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Khan Amin
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S